[Prevention and treatment of renal osteodystrophy: present and future].
Fernández
E
E
Hospital Universitario Arnau de Vilanova de Lleida y Departamento de Medicina de la Universidad de Lleida. efernandez@arnau.scs.es
Craver
L
L
D000535:Aluminum / Q000009:adverse effects; D016723:Bone Remodeling; D002117:Calcitriol / Q000097:blood; D002118:Calcium / Q000097:blood; D012080:Chronic Kidney Disease-Mineral and Bone Disorder / Q000188:drug therapy / Q000209:etiology / Q000517:prevention & control*; D019468:Disease Management; D018450:Disease Progression; D005544:Forecasting; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000209:etiology / Q000517:prevention & control; D007676:Kidney Failure, Chronic / Q000150:complications / Q000628:therapy; D010018:Osteomalacia / Q000378:metabolism; D010281:Parathyroid Hormone / Q000097:blood; D010758:Phosphorus / Q000097:blood; D017410:Practice Guidelines as Topic; D006435:Renal Dialysis / Q000009:adverse effects; D014807:Vitamin D / Q000031:analogs & derivatives / Q000097:blood / Q000627:therapeutic use
D010281:Parathyroid Hormone; D014807:Vitamin D; D010758:Phosphorus; C104450:25-hydroxyvitamin D; D000535:Aluminum; D002117:Calcitriol; D002118:Calcium